ZAMBON, Alfonso
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 11.932
EU - Europa 5.731
AS - Asia 5.508
SA - Sud America 786
Continente sconosciuto - Info sul continente non disponibili 170
AF - Africa 143
OC - Oceania 10
Totale 24.280
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 11.643
SG - Singapore 1.702
IT - Italia 1.666
CN - Cina 1.255
GB - Regno Unito 1.097
HK - Hong Kong 976
DE - Germania 793
SE - Svezia 644
BR - Brasile 591
VN - Vietnam 569
PL - Polonia 279
BD - Bangladesh 263
FR - Francia 244
RU - Federazione Russa 222
FI - Finlandia 198
UA - Ucraina 164
KR - Corea 161
CA - Canada 147
IN - India 124
ID - Indonesia 96
BG - Bulgaria 77
NL - Olanda 77
TR - Turchia 71
MX - Messico 70
AR - Argentina 57
IE - Irlanda 47
JP - Giappone 44
ES - Italia 43
EC - Ecuador 39
BE - Belgio 37
IQ - Iraq 35
CO - Colombia 33
ZA - Sudafrica 33
MA - Marocco 31
MY - Malesia 30
AT - Austria 29
VE - Venezuela 25
AE - Emirati Arabi Uniti 23
PK - Pakistan 21
IR - Iran 18
CH - Svizzera 16
DZ - Algeria 15
EG - Egitto 15
TH - Thailandia 15
LT - Lituania 14
CL - Cile 13
JM - Giamaica 13
RO - Romania 13
UZ - Uzbekistan 13
KE - Kenya 12
PH - Filippine 12
TN - Tunisia 12
CR - Costa Rica 11
CZ - Repubblica Ceca 11
PY - Paraguay 11
SA - Arabia Saudita 10
AU - Australia 8
IL - Israele 8
LK - Sri Lanka 8
PE - Perù 8
PT - Portogallo 8
BY - Bielorussia 7
DO - Repubblica Dominicana 7
GE - Georgia 7
JO - Giordania 7
HU - Ungheria 6
RS - Serbia 6
TT - Trinidad e Tobago 6
AZ - Azerbaigian 5
DK - Danimarca 5
ET - Etiopia 5
HN - Honduras 5
KZ - Kazakistan 5
LB - Libano 5
NP - Nepal 5
SV - El Salvador 5
AL - Albania 4
BO - Bolivia 4
GT - Guatemala 4
NI - Nicaragua 4
SC - Seychelles 4
SK - Slovacchia (Repubblica Slovacca) 4
TW - Taiwan 4
AO - Angola 3
BB - Barbados 3
BZ - Belize 3
EE - Estonia 3
KG - Kirghizistan 3
LU - Lussemburgo 3
OM - Oman 3
PA - Panama 3
UY - Uruguay 3
XK - ???statistics.table.value.countryCode.XK??? 3
BH - Bahrain 2
BS - Bahamas 2
CY - Cipro 2
EU - Europa 2
GR - Grecia 2
HR - Croazia 2
LV - Lettonia 2
Totale 24.078
Salva come PNG Salva come JPEG
Città #
Santa Clara 1.144
Singapore 1.112
Ashburn 1.070
Fairfield 1.030
Hong Kong 949
Woodbridge 629
Southend 576
Chandler 568
San Jose 550
Houston 500
Modena 487
Ann Arbor 439
Nyköping 384
Seattle 383
Cambridge 377
Hefei 372
Frankfurt am Main 350
Wilmington 329
Council Bluffs 315
London 294
Warsaw 257
Beijing 256
Jacksonville 228
Dearborn 222
Los Angeles 200
Ho Chi Minh City 191
Chicago 181
Helsinki 176
Dallas 164
The Dalles 148
Hanoi 146
Seoul 140
New York 139
Berlin 106
Bologna 96
San Diego 87
Princeton 75
Reggio Emilia 74
Sofia 74
Bremen 73
Milan 73
Boardman 67
Buffalo 66
Eugene 65
Lauterbourg 65
Jakarta 63
Moscow 60
Salt Lake City 58
Columbus 57
Orem 53
São Paulo 49
Munich 46
Dublin 42
Shanghai 40
Rome 36
Parma 35
Redondo Beach 34
Formigine 33
Atlanta 32
Brussels 32
Tokyo 32
Amsterdam 31
Izmir 31
Redwood City 31
Toronto 31
Da Nang 30
Montreal 29
Tampa 27
Phoenix 26
Chennai 24
Denver 24
Stockholm 24
Vancouver 22
Wimbledon 22
Bomporto 21
Kent 21
Rio de Janeiro 21
Turin 21
Brooklyn 20
Elk Grove Village 20
Newark 20
Norwalk 20
Falls Church 19
Mexico City 17
Nuremberg 17
Voghera 17
Belo Horizonte 16
Des Moines 16
Johannesburg 16
Lappeenranta 16
Florence 15
Guangzhou 15
Haiphong 15
Madrid 15
Paris 15
Manchester 14
Philadelphia 14
Dhaka 13
Guayaquil 13
North Bergen 13
Totale 16.721
Salva come PNG Salva come JPEG
Nome #
1 - ( 5 - TERT - BUTYL - 2 - ARYL - PYRAZOL - 3 - YL ) . 3 - 12 - FLUORO - 4 - [ ( 3 - OXO - 4H - PYRIDO [ 2 . 3 - BJPYRAZIN - 8 - YL ) OXY | PHENYLJUREA DERIVATIVES AS RAF INHIBITORS FOR THE TREATMENT OF CANCER 1.036
Anti-metastatic Inhibitors of Lysyl Oxidase (LOX): Design and Structure-Activity Relationships 605
Chiral polycyclic ketones via desymmetrization of dihaloolefins 458
Potential of wickerhamomyces anomalus in glycerol valorization 444
Cytocompatibility of potential bioactive cerium-doped glasses based on 45S5 402
Paradox-breaking RAF inhibitors that also target SRC are effective in drug-resistant BRAF mutant melanoma 380
BRAF inhibitors induce metastasis in RAS mutant or inhibitor-resistant melanoma cells by reactivating MEK and ERK signaling 376
A novel protocol for the one-pot borylation/Suzuki reaction provides easy access to hinge-binding groups for kinase inhibitors 350
Nucleoside 2’,3’-cyclic monophosphates in Aphanizomenon flos-aquae detected through nuclear magnetic resonance and mass spectrometry 350
A novel mechanism for the fluxional behaviour of [Pd(η2-tetramethylethylenetetracarboxylate)(2-methylthiomethylpyridine)] 345
Characterization of compound 584, an Abl kinase inhibitor with lasting effects 342
A novel, selective, and efficacious nanomolar pyridopyrazinone inhibitor of V600EBRAF 338
BRAF as a therapeutic target: A patent review (2006-2012) 336
Cerium Containing Bioactive Glasses: A Review 333
Abstract 3704: Novel panRAF inhibitors active in melanomas that are resistant to BRAF-selective, or BRAF-selective/MEK inhibitor combinations 330
BRAF inhibitors based on an imidazo[4,5]pyridin-2-one scaffold and a meta substituted middle ring 328
Mesoporous bioactive glasses doped with cerium: Investigation over enzymatic-like mimetic activities and bioactivity 328
Assessment of chloroaniline toxicity by the submitochondrial particle assay 319
Development of novel, highly potent inhibitors of V-RAF murine sarcoma viral oncogene homologue B1 (BRAF): Increasing cellular potency through optimization of a distal heteroaromatic group 318
Structure Model and Toxicity of the Product of Biodissolution of Chrysotile Asbestos in the Lungs 317
Boosting sunscreen stability: New hybrid materials from UV filters encapsulation 315
1-(5-tert-butyl-2-phenyl-2H-pyrazol-3-yl)-3-[2-fluoro-4-(1-methyl-2-oxo-2,3-dihydro-1H-imidazo[4,5-B]pyridin-7-yloxy)-phenyl]-urea and related compounds and their use in therapy 314
Investigation on the antimicrobial properties of cerium-doped bioactive glasses 312
Novel hinge binder improves activity and pharmacokinetic properties of BRAF inhibitors 305
β-Glucuronidase Pattern Predicted From Gut Metagenomes Indicates Potentially Diversified Pharmacomicrobiomics 297
The discovery of novel, highly potent inhibitors of BRAF 287
Ce-MBGs Loaded with Gentamicin: Characterization and In Vitro Evaluation 285
Development and exploitation of CK2 inhibitors 282
Thiophene based A-D-A small molecules with a dithienosilole core: synthesis, theoretical calculations and optoelectronic properties 278
Synthesis and evaluation of new chiral diols based on the dicyclopentadiene skeleton 277
1-(5-TERT-BUTYL-2-ARYL-PYRAZOL-3-YL)-3-2-FLUORO-4-(3-OXO-4H-PYRIDO2,3-BPYRAZIN-8-YL)OXYPHENYLUREA DERIVATIVES AS RAF INHIBITORS FOR THE TREATMENT OF CANCER 272
Non canonical Cyclic Nucleotides Monophosphates in Aphanizomenon flosaquae: nuclear magnetic resonance and mass spectrometry 263
Novel Potent BRAF Inhibitors: Toward 1 nM Compounds through Optimization of the Central Phenyl Ring 262
Tris-annelated benzenes selectively perfunctionalized on one side only: Hexachlorobenzotrinorbornadiene as a versatile scaffold for the construction of molecular domes 261
"Hexacarboxytrindanes": Benzene rings with homotopic faces as scaffolds for the construction of D3 chiral architectures 258
Synthesis, structure-activity relationship and crystallographic studies of 3-substituted indolin-2-one RET inhibitors 258
Potent BRAF kinase inhibitors based on 2,4,5-trisubstituted imidazole with naphthyl and benzothiophene 4-substituents 257
Bifunctional mesoporous glasses for bone tissue engineering: Biological effects of doping with cerium and polyphenols in 2D and 3D in vitro models 254
RAS Mutations in Cutaneous Squamous-Cell Carcinomas in Patients Treated with BRAF Inhibitors 250
Study on the toxicity of phenolic and phenoxy herbicides using the submitochondrial particle assay 250
Substituted aniline interaction with submitochondrial particles and quantitative structure-activity relationships 245
Novel tricyclic pyrazole BRAF inhibitors with imidazole or furan central scaffolds 245
Pyridoimidazolones as novel potent inhibitors of v-Raf murine sarcoma viral oncogene homologue B1 (BRAF) 243
Gatekeeper mutations mediate resistance to BRAF-targeted therapies 242
Surface acidity modifications induced by thermal treatments and acid leaching on microcrystalline H-BEA zeolite. A FTIR, XRD and MAS-NMR study 241
Efficient access to 5-substituted thiazoles by a novel metallotropic rearrangement 241
Topical 5-Fluorouracil Elicits Regressions of BRAF Inhibitor–Induced Cutaneous Squamous Cell Carcinoma 237
Internal motions in a fulleropyrrolidine tertiary amide with axial chirality 235
Novel oligothiophenes with reduced HOMO-LUMO band gap for Optoelectonics 234
Synthesis of the syn and anti isomer of 1,4,5,8,9,12-hexahydro-2,3,6,7,10,11-hexamethylidene-1,4 : 5,8 : 9,12-trimethanotriphenylene and Diels-Alder reactivity of the syn isomer 234
Loading with Biomolecules Modulates the Antioxidant Activity of Cerium-Doped Bioactive Glasses 232
Isolation and characterization of all eight bisadducts of fulleropyrrolidine derivatives 230
Synthesis and evaluation of antiparasitic activities of new 4-[5-(4-phenoxyphenyl)-2H-pyrazol-3-yl]morpholine derivatives 227
ANTIPROLIFERATIVE COMPOUNDS AND THERAPEUTIC USES THEREOF 224
Small molecule inhibitors of BRAF in clinical trials 223
Nucleophilic reactions at the ring carbons of thiiranium and thiirenium ions. An experimental and theoretical comparison of the S(N)2 and S(N)2-Vin mechanisms 221
Efficient cyclotrimerization of bicyclic vic-bromostannylalkenes promoted by copper(I) thiophen-2-carboxylate 219
Dual Kinase Targeting in Leukemia 218
Inhibiting EGF receptor or SRC family kinase signaling overcomes BRAF inhibitor resistance in melanoma 212
ANTIPROLIFERATIVE COMPOUNDS AND THERAPEUTIC USES THEREOF 210
Qualitative and quantitative discrimination of fake and true alkene rotation processes in pd(η2-olefin) complexes. A new bimolecular mechanism 209
Expedient Access to Type II Kinase Inhibitor Chemotypes by Microwave-Assisted Suzuki Coupling 209
Cytocompatibility of mesoporous bioactive glasses doped with cerium and loaded with polyphenols 204
Evaluation of the Properties of Bioactive Mesoporous Glasses Doped with Cerium and Loaded with Polyphenols 198
Non-canonical Cyclic Nucleoside Monophosphates in Aphanizomenon flos-aquae: nuclear magnetic resonance and mass spectrometry 198
Biostimulants derived from organic urban wastes and biomasses: An innovative approach 194
LYSYL OXIDASE INHIBITORS 191
Erratum: Discovery of Novel α-Carboline Inhibitors of the Anaplastic Lymphoma Kinase (ACS Omega (2022) 7:20 (17083-17097) DOI: 10.1021/acsomega.2c00507) 181
α‐Triazolylboronic Acids: A Novel Scaffold to Target FLT3 in AML 180
Synthetic approach to novel NMP/ALK inhibitors 180
Identification of non-ATP-competitive α-carboline inhibitors of the anaplastic lymphoma kinase 180
Double-ion doped mesoporous glasses: Studies on stability, antibacterial and antioxidant properties, and bioactivity 178
Evaluation of the behaviour of hydrogels containing mesoporous glasses doped with cerium and loaded with polyphenols 176
Paradoxical activation of the MEK/ERK pathway promotes melanoma invasion and metastasis 174
Extraction, purification and in vitro assessment of the antioxidant and anti-inflammatory activity of policosanols from non-psychoactive Cannabis sativa L. 173
Toward the Scale-Up of a Bicyclic Homopiperazine via Schmidt Rearrangement and Photochemical Oxaziridine Rearrangement in Continuous-Flow 173
Rational design of inhibitors of the anaplastic lymphoma kinase 169
NON CANONICAL CYCLIC NUCLEOTIDES MONOPHOSPHATES IN APHANIZOMENON FLOS-AQUAE: NUCLEAR MAGNETIC RESONANCE AND MASS SPECTROMETRY 169
endo-1-Phenylborneol as a novel, alternative chiral auxiliary for the aza-Diels-Alder reaction 167
Dual loaded Ce-MBGs with bioactivity, antioxidant and antibacterial properties 159
Novel ligands from direct benzylic functionalisation of tris(2-pyridylmethyl)amine 152
Discovery of Novel α-Carboline Inhibitors of the Anaplastic Lymphoma Kinase 152
Preparation of 1-​(5-​tert-​butyl-​2-​aryl-​pyrazol-​3-​yl)​-​3-​[2-​fluoro-​4-​[(3-​oxo-​4H-​pyrido[2,​3-​b]​pyrazin-​8-​yl)​oxy]​phenyl]​urea derivatives as RAF inhibitors for treating cancer 146
PROCESS FOR THE PREPARATION OF 8-(4-AMINOPHENOXY)-4H PYRIDO2,3-B PYRAZIN-3-ONE DERIVATIVES 144
The paradox-breaking panRAF plus SRC family kinase inhibitor, CCT3833, is effective in mutant KRAS-driven cancers 141
New pan-ALK inhibitor-resistant EML4::ALK mutations detected by liquid biopsy in lung cancer patients 138
Materiale fotoassorbente ad ampio spettro, procedimento per la sua preparazione ed usi relativi 133
Erratum: Paradox-Breaking RAF Inhibitors that Also Target SRC Are Effective in Drug-Resistant BRAF Mutant Melanoma (Cancer Cell (2015) 27(1) (85–96) (S1535610814004577) (10.1016/j.ccell.2014.11.006)) 129
Polyphosphate coacervate gels for manufacturing of manganese loaded glass powders and fibres: structural, cytocompatibility and surface bioactivity study 129
Corrections to pyridoimidazolones as novel potent inhibitors of v-raf murine sarcoma viral oncogene homologue B1 (BRAF) (Journal of Medicinal Chemistry (2009) 52, (2255-2256) DOI: 10.1021/jm801509w) 124
Long-term durability of discarded cork-based composites obtained by geopolymerization 123
Erratum: Topical 5-fluorouracil elicits regressions of BRAF inhibitor-induced cutaneous squamous cell carcinoma (Journal of Investigative Dermatology (2013) 133 (274-276) DOI: 10.1038/jid.2012.268;0 109
Dual-functional cerium-containing mesoporous bioactive glasses for drug delivery 109
Repurposing pexmetinib as an inhibitor of TKI-resistant BCR::ABL1 104
Enhanced bone regeneration with cerium-doped bioactive glasses: In vitro and in vivo study 103
Targeting monocarboxylate transporter 1 with a copper-chelating coumarin-based bioconjugate: Synthesis and characterization 99
Gelatin/Cerium-Doped Bioactive Glass Composites for Enhancing Cellular Functions of Human Mesenchymal Stem Cells (hBMSCs) 95
Hb Monza: A novel extensive HBB duplication with preserved α-β subunit interaction and unstable hemoglobin phenotype 93
Negative Allosteric Modulators of A2AR: A New Weapon for Cancer Immunotherapy? 76
Discovery of selective, metabolically stable pyrazole-based FLT3 inhibitors for the treatment of acute myeloid leukemia 69
Totale 24.215
Salva come PNG Salva come JPEG
Categoria #
all - tutte 87.520
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 87.520
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2021/20221.361 0 0 201 58 73 89 99 82 188 96 288 187
2022/20231.967 245 218 134 187 258 249 71 176 246 46 76 61
2023/20241.625 52 94 110 97 514 43 278 178 43 48 52 116
2024/20254.053 126 43 125 203 806 566 214 319 564 224 398 465
2025/20268.274 425 326 694 901 1.077 999 887 422 736 765 634 408
2026/20271.069 325 722 22 0 0 0 0 0 0 0 0 0
Totale 24.280